Navigation Links
Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacell's ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
Date:7/21/2008

s therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of Par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with BL&H Co. Ltd. for Korea, Taiwan and Hong Kong, USP Pharma Spolka Z.O.O., an affiliate of US Pharmacia, for Eastern Europe, GENESIS Pharma, S.A. for Southeastern Europe, and Megapharm Ltd. for Israel.

ONCONASE has been granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmaceutical product candidate that works in a manner similar to RNA interference (RNAi) through late-stage clinical trials. The product candidate, ONCONASE, is an RNase that overcomes the challenges of targeting RNA for therapeutic purposes while enabling the development of a new class of targeted therapies for cancer and other life-threatening diseases. Alfacell has completed Phase III clinical trials of ONCONASE in unresectable malignant mesothelioma and, in addition to ongoing efforts to complete the related rolling New Drug Application, Alfacell is currently planning for Phase II clinical trials in other oncology indications. For more information, visit http://www.alfacell.com.

Safe Harbor

This press release includes statements that may constitute "forward- looking" statements, usually containing the words
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
2. Rexinoid Developed by NuRx Pharmaceuticals Shows Promise in Prevention, Treatment of Lung, Breast Cancer, Paper in Clinical Cancer Research Reports
3. Bionovo Announces Publication of the Paper Detailing the Mechanism of Action of Its Cancer Drug BZL101
4. Biomoda to Present Paper on Enhanced Technology for Early Detection of Lung Cancer at Annual SWARM Meeting
5. Journal of Antimicrobial Chemotherapy Paper Supports Additional Role for Cethromycin as Potential Treatment for Infections Caused by Community- Associated Methicillin Resistant Staphylococcus Aureus (CA-MRSA)
6. BD Announces FDA 510(K) Submission of Rapid Molecular Test to Identify Patients Carrying Staph Superbug Prior to Surgery
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
9. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
10. Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
11. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Insulet Corporation (NASDAQ: PODD ), the ... ® Insulin Management System, today announced preliminary revenue ... The Company also announced that it will postpone the ... conference call from Thursday, July 30, as originally scheduled. ... , Preliminary second quarter revenue ...
(Date:7/29/2015)... 2015  UBM Canon brings MEDevice San Diego Conference ... Marina on September 1-2, 2015, with a multi-track conference ... the Business Development track will be a panel on ... Investors, featuring Renee Ryan , Vice President of ... Ahrens , Partner, Canaan Partners; and Jordan Kramer ...
(Date:7/29/2015)... 2015  According to data released today by the ... monthly Medicare Part D premium is expected to remain ... originally projected, the Pharmaceutical Care Management Association (PCMA) said. ... be a bright spot in American health care. By ... and using cutting edge, cost-saving tools like pharmacy networks ...
Breaking Medicine Technology:Insulet Reports Preliminary Second Quarter 2015 Revenue Results 2Insulet Reports Preliminary Second Quarter 2015 Revenue Results 3Insulet Reports Preliminary Second Quarter 2015 Revenue Results 4Insulet Reports Preliminary Second Quarter 2015 Revenue Results 5MEDevice San Diego Offers Tips on Securing Financial Backing from Investors 2
(Date:7/30/2015)... ... July 30, 2015 , ... Gummy smile surgeon, Dr. Alex Farnoosh, ... surgery, as well as the patented gum depigmentation treatmet. Dr. Farnoosh is a renowned ... many patients from around the world. , “Like treatment of any other disease or ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... Mount Sinai Earns National Cancer Institute Designation , The Tisch Cancer Institute (TCI) ... National Cancer Institute (NCI)-designated cancer center. TCI joins an elite group of 69 ...
(Date:7/30/2015)... ... ... Bird B Gone, the leader in bird control products for commercial, industrial and ... from the AC units and ventilation systems on hospital roofs. Bird droppings can carry ... virus. When these droppings dry, the fine powder can be carried into hospitals via ...
(Date:7/30/2015)... , ... July 30, 2015 , ... ... at multinational organizations and NGO’s, according to a new survey by leading international ... that property damage and employee medical expenses represented the largest sources of financial ...
(Date:7/30/2015)... ... 30, 2015 , ... After a three year trial designed to study the ... as the “bionic eye,” researchers have determined the trial to be a success, and ... or already affected by complete vision loss as a result of Retinitis pigmentosa. The ...
Breaking Medicine News(10 mins):Health News:Gummy Smile Dentist, Alex Farnoosh DMD, is Now Offering Comprehensive Treatment Options for Gummy Smiles 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 2Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 3Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 4Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 5Health News:The Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai Earns National Cancer Institute Designation 6Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 2Health News:New Clements Worldwide Global Risk Survey Shows Political Risk and Instability Top Managers' Concerns 3Health News:The Vision Enhancing “Bionic Eye” Deemed Safe For Long Term Use After Three Year Clinical Trial 2
... (April 19, 2010) -- The University of South Florida (USF) ... health records, with the support of a $5.9 million ... last week. "The University of South Florida is the ... and now is one of just a handful of universities ...
... ... the MTA,s zero-tolerance policy on the usage of cell phones despite this driver,s violent disagreement ... New ... being told by a supervisor that he should not talk on the phone while driving. ...
... at the University of Alabama at Birmingham (UAB) Department ... that will help predict which patients are more likely ... The findings also shed light on the genetics that ... with Caucasians, the researchers said. In data presented ...
... activity in the brain can affect language development in ... more frequently on children with severe language impairment to ... reveals a thesis from the Sahlgrenska Academy at the ... children of varying ages, divided into groups. The first ...
... smoke-free settings, but doctors have concerns, , MONDAY, April ... Reynolds launched Camel Orbs, dissolvable nicotine pellets flavored with ... smokers who find themselves in smoke-free surroundings. , But ... Pediatrics warn that the product, which can ...
... at the University of Alabama at Birmingham (UAB) Department ... that will help predict which patients are more likely ... The findings also shed light on the genetics that ... with Caucasians, the researchers said. In data presented ...
Cached Medicine News:Health News:PaperFree Florida to help move physicians towards electronic health records 2Health News:PaperFree Florida to help move physicians towards electronic health records 3Health News:David Perecman Comments On Bus Driver Assaulting Supervisor In New York 2Health News:UAB researchers find 4 biomarkers important in colorectal cancer treatment prognosis 2Health News:Language dysfunction in children may be due to epileptic brain activity 2Health News:Kids Could Overdose From Nicotine-Laced 'Candy' 2Health News:UAB researchers find 4 biomarkers important in colerectal cancer treatment prognosis 2
... of any biological activity but appears to ... of insulin. Although insulin and C-Peptide are ... fasting levels of C-Peptide are 5-10 fold ... the longer half-life of C-Peptide. The glucagon ...
... The Array Multifocal IOL was designed ... with independence from glasses in most situations. ... IOL is similar to that of a ... usually much better and about 19 in ...
Inquire...
... IgG Enzymelinked Immunosorbent Assays(ELISA) is intended for ... antibody to Measles Rubeola) virus in human ... for the determination of immune status. Paired ... demonstrate seroconversion or a significant rise in ...
Medicine Products: